Appeal No. 1997-2801
Application 08/364,072
17$-(N-1,1-diethylbutylcarbamoyl)-4-aza-4-methyl-5"-androst-1-en-3-one;
17$-(N-1,1-diethylbutylcarbamoyl)-4-aza-5"-androst-1-en-3-one;
17$-(N-tert-hexylcarbamoyl)-4-aza-4-methyl-5"-androst-1-en-3-one;
17$-(N-tert-hexylcarbamoyl)-4-aza-5"-androst-1-en-3-one;
17$-(N-2-adamantylcarbamoyl)-4-aza-5"-androst-1-en-3-one,
17$-(N-1-adamantylcarbamoyl)-4-aza-5"-androst-1-en-3-one,
17$-(N-2-norbornylcarbamoyl)-4-aza-5"-androst-1-en-3-one, or
17$-(N-1-norbornylcarbamoyl)-4-aza-5"-androst-1-en-3-one,[.]1
4. A method according to Claim 3 wherein the compound is
17$-(N-tertbutylcarbamoyl)-4-aza-5"-androst-1-en-3-one.
The examiner relied on the following reference:
Johnson 5,300,294 Apr. 5, 1994
(filed Jun. 27, 1990)
The references relied upon by this merits panel are:
Rasmusson et al. (Rasmusson) 4,760,071 Jul. 26, 1988
Eur. Pat. App. (EP’383) 0 285 383 Oct. 5, 1988
Illustrated Stedman’s Medical Dictionary (Stedman), 24th Edition, Williams & Wilkins,
Baltimore (1982), pp. 675-677.
Claims 1 through 8 stand rejected under 35 U.S.C. § 103. The examiner relies
upon Johnson as evidence of obviousness. Claims 1 through 8 stand provisionally
rejected under 35 U.S.C. § 101(double patenting) over claims 1 through 8 of copending
application Serial No. 08/104,964. We reverse the section 103 rejection. The double
1The record copy of claim 3 does not have a terminal period.
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007